Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,016.50
    -887.23 (-1.00%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

ACCESSWIRE

Stock Research Monitor: AYTU, BCRX, and BLCM

LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. On Monday, benchmark US indices were mixed as the NASDAQ Composite closed the trading session up 0.28%; the Dow Jones Industrial Average edged 0.06% lower; and the S&P 500 was up 0.18%. US markets sawsixout of nine sectors finishing the day inred and three in green. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aytu BioScience Inc. (NASDAQ: AYTU), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

AVEO Pharmaceuticals

Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc.'s stock finished Monday's session 11.68% higher at $2.39. A total volume of 5.10 million shares was traded, which was above its three months average volume of 2.26 million shares. The Company's shares have advanced 3.91% in the past month. The stock is trading above its 50-day moving average by 3.60%. Furthermore, shares of AVEO Pharma, which develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need, have a Relative Strength Index (RSI) of 49.69. Get the full research report on AVEO for free by clicking below at:

ADVERTISEMENT

www.wallstequities.com/registration/?symbol=AVEO


Aytu BioScience

Shares in Englewood, Colorado-based Aytu BioScience Inc. ended at $0.28, down 4.48% from the last trading session. The stock recorded a trading volume of 344,018 shares. The stock is trading below its 50-day moving average by 13.04%. Moreover, shares of Aytu BioScience, which focuses on developing and commercializing novel products in the field of urology in the US, have an RSI of 44.97. Gain free access to the research report on AYTU at:


www.wallstequities.com/registration/?symbol=AYTU


BioCryst Pharmaceuticals

Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s stock ended yesterday's session 0.67% lower at $5.90 with a total trading volume of 387,611 shares. The Company's shares have advanced 20.41% over the previous three months. The stock is trading above its 200-day moving average by 12.93%. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 46.97.

On July 17th, 2018, research firm Bank of America/ Merrill upgraded the Company's stock rating from ‘Underperform' to ‘Neutral'. Register for your free report coverage on BCRX at:

www.wallstequities.com/registration/?symbol=BCRX


Bellicum Pharmaceuticals

On Monday, shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. recorded a trading volume of 590,884 shares. The stock finished the day 3.78% lower at $7.13. The stock is trading below its 50-day moving average by 12.95%. Furthermore, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have an RSI of 33.30. Get the free research report on BLCM at:

www.wallstequities.com/registration/?symbol=BLCM

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities